文章：

他汀类药物对接受索拉非尼或仑伐替尼治疗的晚期肝细胞癌患者生存期的影响

The Impact of Statins on the Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib or Lenvatinib

原文发布日期：5 January 2024

DOI: 10.3390/cancers16020249

类型: Article

开放获取: 是

英文摘要：

We aimed to evaluate the survival benefits of coadministering statins and multityrosine kinase inhibitors (TKIs) in patients with advanced hepatocellular carcinoma (HCC). Data from the Health Insurance Review and Assessment Service in Korea (2010–2020) were utilized. Statin use (≥28 cumulative defined daily doses) was analyzed, with 1534 statin users matched to 6136 non-users (1:4 ratio) using propensity scores. Primary and secondary outcomes were overall survival (OS) and progression-free survival (PFS). Statin use significantly improved OS (hazard ratio [HR] 0.77, 95% confidence interval [CI] 0.72–0.82,p< 0.001) and PFS (HR 0.78, 95% CI 0.74–0.84,p< 0.001). Continuous or post-TKI statin users had better OS, while discontinuation after TKI use led to poorer OS. Both lipophilic and hydrophilic statins improved OS and PFS, particularly with ≥730 cumulative defined daily doses. In conclusion, combining statins and TKIs in patients with advanced HCC yielded significant survival benefits, influenced by statin dosage and duration. Continuous statin administration post-TKI treatment is crucial for improving outcomes in patients with HCC.

摘要翻译： 

本研究旨在评估晚期肝细胞癌（HCC）患者联合使用他汀类药物与多靶点酪氨酸激酶抑制剂（TKIs）的生存获益。研究数据来源于韩国健康保险审查与评估服务数据库（2010–2020年）。对他汀类药物使用情况（累计限定日剂量≥28）进行分析，通过倾向评分匹配将1534名他汀类药物使用者与6136名非使用者按1:4比例进行匹配。主要和次要结局指标分别为总生存期（OS）和无进展生存期（PFS）。结果显示，他汀类药物使用显著改善OS（风险比[HR] 0.77，95%置信区间[CI] 0.72–0.82，p<0.001）和PFS（HR 0.78，95% CI 0.74–0.84，p<0.001）。持续使用或TKI治疗后使用他汀类药物的患者OS更佳，而TKI治疗后停用他汀类药物则导致OS较差。亲脂性和亲水性他汀类药物均能改善OS和PFS，尤其在累计限定日剂量≥730时效果更为显著。结论表明，晚期HCC患者联合使用他汀类药物与TKIs可带来显著的生存获益，该效果受他汀类药物剂量和治疗持续时间的影响。TKI治疗后持续使用他汀类药物对于改善HCC患者预后至关重要。

原文链接：

The Impact of Statins on the Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib or Lenvatinib